KIC
AZN icon

Keating Investment Counselors’s AstraZeneca AZN Stock Holding History

Keating Investment Counselors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,709
Closed -$503K – 72
2024
Q1 		$503K Sell
3,709
-138
-4% -$18.3K 0.16% 56
2023
Q4 		$518K Sell
3,847
-37
-1% -$4.81K 0.19% 63
2023
Q3 		$526K Buy
+3,884
New +$530K 0.18% 60
2021
Q2 		– Sell
-2,245
Closed -$223K – 61
2021
Q1 		$223K Sell
2,245
-350
-13% -$35.2K 0.11% 58
2020
Q4 		$259K Hold
2,595
– – 0.13% 55
2020
Q3 		$284K Hold
2,595
– – 0.15% 51
2020
Q2 		$274K Buy
2,595
+152
+6% +$15.7K 0.15% 50
2020
Q1 		$218K Sell
2,443
-1,575
-39% -$148K 0.13% 59
2019
Q4 		$401K Sell
4,018
-50
-1% -$4.71K 0.18% 56
2019
Q3 		$363K Sell
4,068
-850
-17% -$73.7K 0.16% 57
2019
Q2 		$406K Sell
4,918
-6,945
-59% -$545K 0.18% 53
2019
Q1 		$959K Sell
11,863
-28,192
-70% -$2.22M 0.43% 45
2018
Q4 		$3.04M Sell
40,055
-14,063
-26% -$1.1M 1.54% 27
2018
Q3 		$4.28M Sell
54,118
-59,925
-53% -$4.53M 1.84% 24
2018
Q2 		$8.01M Sell
114,043
-10,287
-8% -$740K 3.8% 8
2018
Q1 		$8.7M Sell
124,330
-4,750
-4% -$329K 4.01% 6
2017
Q4 		$8.96M Sell
129,080
-100
-0.1% -$6.74K 3.81% 6
2017
Q3 		$8.75M Sell
129,180
-1,600
-1% -$101K 3.8% 5
2017
Q2 		$8.92M Sell
130,780
-1,013
-0.8% -$66.2K 3.9% 6
2017
Q1 		$8.21M Buy
131,793
+1,100
+0.8% +$64K 3.66% 6
2016
Q4 		$7.14M Buy
130,693
+5,868
+5% +$333K 3.37% 9
2016
Q3 		$8.2M Buy
124,825
+118,862
+1,993% +$7.77M 3.99% 6
2016
Q2 		$360K Buy
+5,963
New +$346K 0.18% 58

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Keating Investment Counselors's AZN Position: Q2 2024 in Review

Keating Investment Counselors sold out of AstraZeneca (AZN) in Q2 2024, closing a stake of 3,709 shares — an estimated $503K sold.

Keating Investment Counselors first reported a position in AZN in Q2 2016 and held it in 23 quarters. The position peaked at $8.96M in Q4 2017. 1,212 funds tracked by Wall St. Rank hold AZN as of Q2 2024.

  • Keating Investment Counselors reported no remaining AstraZeneca position as of Q2 2024 after selling out during the quarter.
  • Keating Investment Counselors sold 3,709 AstraZeneca shares in Q2 2024, an estimated $503K.
  • Keating Investment Counselors first reported a position in AstraZeneca in Q2 2016 and held it in 23 quarters.
  • Keating Investment Counselors's AstraZeneca position peaked at $8.96M in Q4 2017.
  • 1,212 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2024.

Based on Keating Investment Counselors's 13F filing for Q2 2024, filed 6 Aug 2024.